NCT00539669View on ClinicalTrials.gov

TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian

PHASE2CompletedINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

March 31, 2003

Conditions

Ovarian Neoplasms

Interventions

DRUG

Docetaxel

Trial Locations (1)

Unknown

Sanofi-Aventis, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY

NCT00539669 - TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian | Biotech Hunter | Biotech Hunter